| Kimberly Ann Slusser, CNS | |
|
201 Colonial Dr, Walnut Ridge, AR 72476-1410 | |
| (870) 886-5507 | |
| (870) 886-5632 |
| Full Name | Kimberly Ann Slusser |
|---|---|
| Gender | Female |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 5 Years |
| Location | 201 Colonial Dr, Walnut Ridge, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457905465 | NPI | - | NPPES |
| 121619 | Other | AR | AR STATE BOARD OF NURSING |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 121619 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lawrence Memorial Hospital | Walnut ridge, AR | Hospital |
| St Bernards Medical Center | Jonesboro, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| 1st Choice Healthcare Inc | 0648184218 | 32 |
News Archive
Financial toxicity among breast cancer patients is independently associated with worse psychological well-being following a mastectomy or lumpectomy operation.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Researchers at the RIKEN Brain Science Institute (BSI) and their collaborators have shed light on the function of a little-studied amyloid peptide in promoting Alzheimer's disease.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
The Icahn School of Medicine at Mount Sinai has been awarded nearly $1.7 million in grant funding from the U.S. Department of Defense to study how bladder cancer affects certain types of white blood cells called "natural killer" cells, or NK cells, which control and limit tumor growth.
› Verified 8 days ago
| Entity Name | 1st Choice Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942256508 PECOS PAC ID: 0648184218 Enrollment ID: O20100427000059 |
News Archive
Financial toxicity among breast cancer patients is independently associated with worse psychological well-being following a mastectomy or lumpectomy operation.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Researchers at the RIKEN Brain Science Institute (BSI) and their collaborators have shed light on the function of a little-studied amyloid peptide in promoting Alzheimer's disease.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
The Icahn School of Medicine at Mount Sinai has been awarded nearly $1.7 million in grant funding from the U.S. Department of Defense to study how bladder cancer affects certain types of white blood cells called "natural killer" cells, or NK cells, which control and limit tumor growth.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Ann Slusser, CNS Po Box 83, Corning, AR 72422-0083 Ph: (870) 857-3334 | Kimberly Ann Slusser, CNS 201 Colonial Dr, Walnut Ridge, AR 72476-1410 Ph: (870) 886-5507 |
News Archive
Financial toxicity among breast cancer patients is independently associated with worse psychological well-being following a mastectomy or lumpectomy operation.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Researchers at the RIKEN Brain Science Institute (BSI) and their collaborators have shed light on the function of a little-studied amyloid peptide in promoting Alzheimer's disease.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
The Icahn School of Medicine at Mount Sinai has been awarded nearly $1.7 million in grant funding from the U.S. Department of Defense to study how bladder cancer affects certain types of white blood cells called "natural killer" cells, or NK cells, which control and limit tumor growth.
› Verified 8 days ago